News

Verona says RPL554 could treat cystic fibrosis

Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, “The presentation, entitled ‘CFTR activation by the dual phosphodiesterase 3/4 inhibitor RPL554 and the MRP4 inhibitor MK571,’ reports data demonstrating the . . . Read more

Bespak parent company Consort Medical to acquire Aesica

Consort Medical, the parent company of device supplier Bespak, has announced that it will acquire CDMO Aesica Pharmaceuticals for £230 million, with the deal expected to be complete in November, 2014. Aesica offers development and manufacturing services for a range of OINDPs, including DPIs, inhalation solutions, and intranasal products. Aesica CEO Robert Hardy commented, “We . . . Read more

CHMP recommends approval of Duaklir Genuair inhaler

Almirall has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. Almirall will market the product as Duaklir Genuair and Brimica Genuair in Europe. Almirall Chief Scientific Officer Thomas Eichholtz said, “We are very pleased with the . . . Read more